Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.

MLA

Jungsil Ro, et al. “Clinical Outcomes of HER2-Positive Metastatic Breast Cancer Patients with Brain Metastasis Treated with Lapatinib and Capecitabine: An Open-Label Expanded Access Study in Korea.” BMC Cancer, vol. 12, no. 1, Jan. 2012, pp. 322–32. EBSCOhost, https://doi.org/10.1186/1471-2407-12-322.

APA

Jungsil Ro, Sohee Park, Sung- Bae Kim, Tae You Kim, Young Hyuk Im, Sun Young Rha, Joo Seop Chung, Hanlim Moon, & Santillana, S. (2012). Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC Cancer, 12(1), 322–332. https://doi.org/10.1186/1471-2407-12-322

Chicago

Jungsil Ro, Sohee Park, Sung- Bae Kim, Tae You Kim, Young Hyuk Im, Sun Young Rha, Joo Seop Chung, Hanlim Moon, and Sergio Santillana. 2012. “Clinical Outcomes of HER2-Positive Metastatic Breast Cancer Patients with Brain Metastasis Treated with Lapatinib and Capecitabine: An Open-Label Expanded Access Study in Korea.” BMC Cancer 12 (1): 322–32. doi:10.1186/1471-2407-12-322.